Search Result

According to UNAIDS, there were approximately 37.9 million people across the globe with HIV/AIDS in 2018. Of these, 36.2million were adult and 1.7 million were children (<15years old). New HIV infection – An estimated 1.7 million individuals worldwide were newly infected with HIV in 2018.Blood coagulation abnormalities occur frequently in people infected with Human Immunodeficiency Virus (HIV). Researches so far shows the retrovirus is associated with endothelial dysfunction and liver damage. Both endothelial dysfunction and liver damage can result in coagulation defect because most coagulation factors are produced in the liver and some are activated by the tissues therefore default to them can lead to coagulation defect. It is therefore expected that as HIV progresses coagulation abnormalities increases. However, few studies showed the association of these abnormalities with antiretroviral therapy (ART). Prothrombin time (PT) and partial thromboplastin time with kaolin (PTTK) use to assess the extrinsic and intrinsic pathway respectively alongside with platelet count help to screen for coagulation abnormalities in HIV infected person. The intrinsic pathway comprising of factor I,II,IX,X,XI and factor XII while the extrinsic pathway comprising of factor I,II,V,VIII and factor X. HIV-related thrombocytopenia (Tr-HIV) is the most common haemostatic disorder with a high morbidity and affects patients from every risk group independently of age, sex, or stage of infection. Two mechanisms are responsible for the Tr-HIV: bone marrow failure and immunological disorders, namely, circulating immune complex deposited on the platelet membrane and the production of autoantibodies directed against platelets.

Antiretroviral therapy (ART) has revolutionized the management of human immunodeficiency virus (HIV) infection, significantly reducing morbidity and mortality rates worldwide. However, emerging evidence suggests that ART may be associated with alterations in platelet function and homeostasis, leading to platelet aberrations such as thrombocytopenia and platelet hyperactivity in HIV patients. This review provides a comprehensive overview of the relationship between ART and platelet aberrations in HIV-infected individuals. We discuss the epidemiology, pathogenesis, clinical manifestations, and management strategies of platelet abnormalities associated with ART, including immune reconstitution inflammatory syndrome (IRIS)-related thrombocytopenia and ART-induced coagulation disorders. Furthermore, we explore potential mechanisms underlying ART-induced platelet aberrations, including direct drug toxicity, immune-mediated mechanisms, and viral factors. Understanding the impact of ART on platelet function and homeostasis is essential for optimizing the management of HIV-infected individuals and minimizing the risk of associated complications.